ABCL
Abcellera Biologics Inc
13.70$
-1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.6% | -1.7% | -3.5% | -1.4% | -2.3% | -1.2% | +4.3% | -3.3% | +0.1% | -3.7% | +0.0% | |
| – | -5.2% | -6.7% | -5.2% | -3.7% | +1.1% | +1.8% | -3.0% | -6.3% | +4.8% | -8.7% | +2.2% | |
| – | -22.7% | -7.3% | +20.0% | -14.6% | +23.4% | +1.9% | -42.0% | -10.0% | +54.5% | -40.0% | +55.8% | |
| – | -3.2% | -8.2% | -4.0% | -4.1% | -2.7% | -3.3% | -8.6% | -10.4% | +7.7% | -5.5% | +7.0% | |
| – | -14.7% | +6.8% | -1.6% | -6.6% | +45.7% | +37.4% | +21.1% | +3.9% | -3.7% | -24.6% | -17.5% | |
| – | -7.3% | -33.3% | -100.0% | – | – | – | – | – | – | +24.1% | -3.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -2.9% | -1.4% | -27.9% | -38.6% | -19.9% | -2.2% | -2.3% | -2.3% | -2.4% | -2.4% | -2.5% | |
| – | +1.9% | -0.8% | -9.5% | +4.4% | -3.3% | +5.5% | +23.0% | -0.8% | -0.5% | -5.4% | +11.5% | |
| – | +8.0% | -11.9% | -32.9% | +13.1% | -3.7% | -1.6% | -11.1% | +2.7% | -6.5% | -26.5% | +12.5% | |
| – | +10.5% | -10.2% | +1.3% | -8.5% | -9.8% | +0.3% | +5.6% | +5.5% | +12.6% | +0.9% | -3.4% | |
| – | +64.1% | -5.9% | -1.2% | +30.9% | -1.3% | -4.5% | -2.3% | -0.8% | -20.6% | -17.5% | -41.8% | |
| – | -2.6% | -1.9% | -1.7% | -3.0% | -2.0% | -3.1% | -1.6% | -4.3% | +0.3% | -3.0% | -4.5% | |
| – | -14.4% | -14.5% | -15.4% | -25.3% | -22.6% | -39.0% | -48.7% | -156.1% | – | – | – | |
| – | +0.5% | +0.6% | +0.5% | +0.2% | -0.1% | +1.1% | +0.3% | +0.1% | -0.1% | +1.5% | +0.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.